In this issue of AJKD, Wang et al1 report on the incidence, trends, and consequences of treatment of posttransplant hyperparathyroidism in a nationwide registry encompassing 30,127 Medicare-insured US patients who received a first kidney transplant. The 2 treatments of interest were cinacalcet use and parathyroidectomy in the first 3 years following kidney transplantation. The authors report that cinacalcet use was common (18%) and increased by 20% from 2007 to 2013, with treatment most often initiated early in the posttransplant course (a median of 6.8 weeks).